Stay updated on TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial page.

Latest updates to the TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page history shows a new revision v3.3.3 on 2025-12-19 with a Study Status entry added. The HHS Vulnerability Disclosure link (revision v3.3.2) was removed on 2025-12-05.SummaryDifference0.3%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA new version (55) was added, updating the Study Status and Contacts/Locations for NCT04919512.SummaryDifference0.2%

- Check34 days agoChange DetectedThe page now shows Revision: v3.3.2 where it previously displayed Revision: v3.3.1.SummaryDifference0.1%

- Check42 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.1 with no changes to study data or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedVersion history shows a new 'Study Status' entry (version 54) added on 2025-11-07, and a government funding outage notice from 2025-10-10 was removed. These are administrative UI/content changes and do not alter the underlying study data.SummaryDifference0.6%

- Check63 days agoChange DetectedThe new screenshot shows additional entries in the Study Record History list, extending the history of submitted versions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial page.